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Presence of high-ERG expression is an independent unfavorable prognostic marker in
MLL-rearranged childhood myeloid leukemia
Childhood acute myeloid leukemia (AML) is a heterogeneous
disease, in terms of genetic/molecular abnormalities resulting into
marked differences in outcome.1 A myriad of proteins have been
suggested aberrantly regulated in AML, and Ets-related gene
(ERG, 21q22) expression in normal and aberrant hematopoiesis is
currently under evaluation.2 High ERG expression has been
associated with poor prognosis in cytogenetically normal adult
AMLs.3,4 Only recently, Staffas et al reported that ERG expression
was associated with an inferior probability of event-free survival
(EFS) in northern European children with AML, although not as
independent prognostic factor.5 We measured ERG expression in a
cohort of 268 Italian pediatric patients (141 males and 127 females,
median age at diagnosis 6 years, range 7 days-22 years) with newly
diagnosed de novo AML enrolled in AIEOP LAM-2002 protocol.6
ERG expression, relative to ABL, was measured by real-time
quantitative–PCR and calculated the relative quantity (RQ) by the
comparative Ct method. ERG expression turned out to be
higher (high-ERG, RQ  1) or lower (low-ERG, RQ  1) in
AML patients, dividing them into 2 groups significantly differ-
ent (N high-ERG  162, RQ 4927, N low-ERG  106, RQ 0371,
P  .007). Patients were then divided into cytogenetic groups. Of
these, 157 carried well-known molecular markers, such as Core
Binding Factor (CBF) anomalies (n 52), FLT3-ITD (n 34)
and the mixed-lineage leukemia gene (MLL) rearrangements
(n  71), whereas the remaining 111 patients were cytogenetically
normal (CN). ERG was found to be different expressed between
each AML subgroups, with statistical significance for all the
subgroups analyzed (Figure 1A, Student t test, statistical signifi-
cance P  .05). Overall Survival (OS), defined as the time from
diagnosis to last follow-up or death, was measured. Results showed
no statistical difference in OS for CN (Kaplan-Meier log-rank test,
P  .58), CBF (P  .82), nor FLT3ITD (P  .54) patients accord-
ing to ERG expression. By contrast, OS and EFS for patients with
MLL-rearrangements and high-ERG expression were found to be
significantly worse than those of patients with low-ERG (P  .001,
Figure 1B) expression. Multivariate analysis by Cox regression
model confirmed that high-ERG expression is an independent
prognostic factor for EFS in MLL-rearranged patients (hazard
risk 4.22, 95% CI 1.10-16.18, P  .036). In multivariate
analysis complex karyotype remained the only other independent
adverse factor in this group (P  .028, HR 3.51, 95%CI 1.15-
10.74). These data indicate that ERG expression strongly influ-
ences the probability of OS and EFS of MLL-rearranged patients.
Since childhood MLL-rearranged AML includes patients with
marked differences in biology and outcome,7,8 we suggest the use
of ERG expression to stratify patient’s prognostic risk and to tailor
therapeutic approaches.
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Figure 1. ERG expression in AML influences EFS of MLL-rearranged patients.
(A) ERG expression in AML subgroups. ERG expression relative to ABL housekeep-
ing gene was measured by real-quantitative PCR. RQ is the relative quantity of ERG
expression with respect to the average of its expression in healthy bone marrows
(N  17) calculated by comparative Ct method. CBF indicates core binding factor
rearrangements; and CN, cytogenetically normal. (B) Probability of event-free
survival in children with MLL-rearranged AML according to ERG expression.
Event-free survival (EFS) for patients MLL-rearranged with high (73.3%) vs low
(18.3%) ERG expression.
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Response:
High ERG gene expression is an unfavorable prognostic marker in pediatric acute myeloid
leukemia
It is with great interest we read the scientific letter by Pigazzi et al
and their finding that high ERG expression is an independent
unfavorable prognostic marker for both event-free and overall
survival in pediatric acute myeloid leukemia (AML) with MLL
(11q23) rearrangement treated within the AIEOP LAM-2002
protocol.1 As the authors also point out, our recent study on
pediatric AML patients enrolled in the NOPHO-1993 or NOPHO-
2004 protocols supports this finding.2 We could show that high
ERG expression is an unfavorable prognostic marker for event-free
survival in this cohort of pediatric AML, where patients with MLL
rearrangement were included.2 And indeed, this observation was
even more pronounced if we analyzed the group of patients with
MLL rearrangement separately for event free survival (Figure 1A,
P  .03). However, there was no significant difference between
low and high ERG expression for overall survival in this group
(P  .16). High ERG expression was not identified as an indepen-
dent marker in our study but this was mainly because BAALC and
ERG were often found coexpressed at high levels, where high
BAALC expression came out as a stronger predictor for prognosis
in the multivariate analysis when the whole pediatric AML cohort
was included. But, importantly, high BAALC was not statistically
significant for event-free survival within the subgroup with MLL
rearrangement (Figure 1B, P  .43) in contrast to ERG. There were
too few patients in the MLL group (n 40) in our study to perform
a meaningful multivariate analysis, so we cannot comment on the
independence of the ERG expression. However, we think that these
2 separate studies now have strengthened the evidence that also
high expression level of ERG is an unfavorable prognostic marker
in pediatric AML, in particular for the important group of patients
with MLL rearrangements. The remaining challenge before gene
expression levels can be used for prognostic stratification for
clinical use is to establish standardized methods for quantitative
Figure 1. Survival according to ERG and BAALC
expression. Event-free survival for AML patients under
the age of 19 with MLL (11q23) rearrangement and high
or low ERG (A) and BAALC (B) expression, respectively.
Patients were diagnosed 1997-2007 in Denmark, Fin-
land, Iceland, Norway, or Sweden. High and low ERG and
BAALC expression were defined as above and below the
median value of all 149 pediatric non-APL AML patients
included in the study.
CORRESPONDENCE 1087BLOOD, 26 JANUARY 2012  VOLUME 119, NUMBER 4
D
ow
nloaded from
 https://ashpublications.org/blood/article-pdf/119/4/1086/1355033/zh800412001086.pdf by U
N
IVER
SITA STU
D
I D
I TO
R
IN
O
 user on 09 April 2020
